Zhangzhou Pientzehuang Pharmaceutical (600436) H1 2025 earnings summary

Executive summary

• Revenue for the first half of 2025 was RMB 5.38 billion, down 4.81% year-over-year; net profit attributable to shareholders was RMB 1.44 billion, down 16.22%.

• The company maintained its leading position in the Chinese medicine sector, with continued brand and R&D investments.

• The company faced dual challenges from healthcare policy adjustments and a shrinking consumer market, leading to a complex and severe operating environment.

• Strategic increases in sales expenses helped maintain core product market share and sales volume resilience.

• Proposed interim cash dividend of RMB 14.00 per 10 shares, totaling RMB 844.64 million, representing 58.56% of net profit.

Financial highlights

• Operating income: RMB 5.38 billion, down 4.81% year-over-year.

• Net profit attributable to shareholders: RMB 1.44 billion, down 16.22% year-over-year.

• Operating profit fell 17.07% year-over-year to RMB 1,711.54 million.

• Basic and diluted EPS: RMB 2.39, down 16.14% year-over-year.

• Gross margin: 40.46%, down 4.37 percentage points year-over-year.

Outlook and guidance

• Management expects continued stable demand in the pharmaceutical sector, with policy support for innovation and traditional Chinese medicine.

• The company will focus on core products, channel expansion, and cost control to drive future growth.

• The company is implementing systematic measures to stabilize costs, enhance operational efficiency, and strengthen market supply.

• Focus remains on long-term value creation and delivering reasonable returns to investors.